Price
No data yet.
Social Signal Score
Revenue
$270.93MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Li Chen
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 328
- Beta
- 0.74
- Country
- CN
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -2.01
Financials
Revenue
$270.93M+2476.6%Net Income
$-76.30MEBITDA
$-63.09MFree Cash Flow
$29.39MEPS (diluted)
$-0.07Shares Outstanding (diluted)
1.06B+0.4%Operating Expenses
$238.12MCash & Debt
$1.09BReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $480.21M | $1.08B | $1.12 |
| 2024 | $255.89M | $-250.14M | $-0.25 |
| 2023 | $76.61M | $-211.23M | $-0.22 |
| 2022 | $17.60M | $-203.77M | $-0.21 |
| 2021 | $0.00 | $-330.95M | $-0.34 |
| 2020 | $8.66M | $-396.43M | $-0.41 |
| 2019 | $22.26M | $-427.90M | $-0.45 |
| 2018 | $9.13M | $-3.60B | $-10.07 |
| 2017 | $10.52M | $-272.71M | $-0.26 |
| 2016 | $595.0K | $-361.33M | $-0.34 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.60
- Implied price
- $28.85
- Return from $0.31
- 147.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $14.34 — today's price is already 97.8% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 107.2% | 116.6% | 124.7% | 131.7% | 138.0% |
| 3.0% | 117.7% | 127.7% | 136.1% | 143.5% | 150.1% |
| 8.0% | 128.3% | 138.7% | 147.6% | 155.3% | 162.3% |
| 13.0% | 138.9% | 149.8% | 159.1% | 167.2% | 174.4% |
| 18.0% | 149.5% | 160.8% | 170.5% | 179.0% | 186.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newsseekingalpha.com·5h ago·Positive
Hua Medicine (Shanghai) Ltd. (HUMDF) Q2 2026 Earnings Call Transcript Hua Medicine (Shanghai) Ltd. (HUMDF) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Thu, Apr 1(in 7 months)
Consensus estimate $0.07 per share
Typical surprise +60.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 20$-0.00 vs $-0.03beat
- Thu, Aug 28$0.17 vs $-0.04beat
- Thu, Mar 27$-0.02 vs $-0.04beat
- Thu, Mar 28$-0.02 vs $0.07miss
- Thu, Aug 24$-0.01 vs $0.05miss
Estimates and results for HUMDF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.